CSIMarket
 


Provention Bio Inc   (PRVB)
Other Ticker:  
 

Provention Bio Inc 's Tangible Leverage Ratio

PRVB's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


Due to net new borrowings of 134.02%, Tangible Leverage Ratio fell to 1.85, above the Provention Bio Inc 's average Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the forth quarter 2022, 373 other companies have achieved lower Tangible Leverage Ratio than Provention Bio Inc in the IV Quarter 2022. While Tangible Leverage Ratio total ranking has deteriorated compared to the third quarter 2022 from 838 to 2185 .

Explain Tangible Leverage Ratio?
What is PRVB Market Share?
What are PRVB´s Total Liabilities?


PRVB Tangible Leverage Ratio (Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity Change -43.75 % 7.95 % -50.21 % -48.76 % -0.31 %
Y / Y Total Liabilities Change 362.12 % 106.82 % 1.52 % -5.57 % 42.66 %
Tangible Leverage Ratio MRQ 1.85 0.34 0.33 0.3 0.22
PRVB's Total Ranking # 2185 # 838 # 658 # 873 # 169
Seq. Tangible Equity Change -56.97 % 83.99 % -16.48 % -14.93 % -17.43 %
Seq. Total Liabilities Change 134.02 % 91.43 % -9.13 % 13.52 % 4.73 %



Tangible Leverage Ratio forth quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 374
Healthcare Sector # 729
Overall Market # 2185


Tangible Leverage Ratio Statistics
High Average Low
0.94 0.19 0.02
(Dec 31 2022)   (Sep 30 2018)




Financial Statements
Provention Bio Inc 's Tangible Equity $ 62 Millions Visit PRVB's Balance sheet
Provention Bio Inc 's Total Liabilities $ 115 Millions Visit PRVB's Balance sheet
Source of PRVB's Sales Visit PRVB's Sales by Geography


Cumulative Provention Bio Inc 's Tangible Leverage Ratio

PRVB's Tangible Leverage Ratio for the trailling 12 Months

PRVB Tangible Leverage Ratio

(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
Y / Y Tangible Equity TTM Growth -43.75 % 7.95 % -50.21 % -48.76 % -0.31 %
Y / Y Total Liabilities TTM Growth 362.12 % 106.82 % 1.52 % -5.57 % 42.66 %
Tangible Leverage Ratio TTM 0.57 0.3 0.25 0.21 0.18
Total Ranking TTM # 743 # 489 # # #
Seq. Tangible Equity TTM Growth -56.97 % 83.99 % -16.48 % -14.93 % -17.43 %
Seq. Total Liabilities TTM Growth 134.02 % 91.43 % -9.13 % 13.52 % 4.73 %


On the trailing twelve months basis Due to the net new borrowings of 134.02% during the trailing twelve months finishing in the IV Quarter 2022, cumulativeTangible Leverage Ratio improved to 0.57, above the Provention Bio Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 8, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Provention Bio Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the IV Quarter 2022, compared to the prior period, from 4 to 46.

Explain Tangible Leverage Ratio?
What is PRVB Market Share?
What are PRVB´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 14
Within the Market # 2185


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
0.11 0.08 0.05
(Dec 31 2022)   (Sep 30 2022)




Companies with similar Tangible Leverage Ratio in the quarter ending Dec 31 2022, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioDec 31 2022 MRQ Total LiabilitiesDec 31 2022 MRQ Tangible Equity
Adc Therapeutics Sa  4.96 $ 440.441  Millions$ 88.727  Millions
Intercept Pharmaceuticals inc   4.95 $ 460.634  Millions$ 93.077  Millions
Aravive Inc   4.83 $ 51.496  Millions$ 10.657  Millions
Summit Therapeutics Inc   4.31 $ 537.514  Millions$ 124.856  Millions
Maravai Lifesciences Holdings Inc   4.28 $ 1,734.009  Millions$ 404.912  Millions
Opko Health Inc   4.26 $ 605.611  Millions$ 142.277  Millions
Omeros Corp  4.17 $ 357.289  Millions$ 85.684  Millions
Emergent Biosolutions Inc   4.04 $ 1,778.600  Millions$ 440.700  Millions
Phibro Animal Health Corporation  3.98 $ 621.801  Millions$ 156.078  Millions
Clearside Biomedical Inc   3.80 $ 40.347  Millions$ 10.607  Millions
Kala Bio inc   3.58 $ 67.846  Millions$ 18.974  Millions
Perrigo Company Plc  3.52 $ 5,667.900  Millions$ 1,611.900  Millions
Apellis Pharmaceuticals Inc   3.48 $ 590.345  Millions$ 169.872  Millions
Ionis Pharmaceuticals Inc  3.42 $ 1,960.989  Millions$ 572.887  Millions
Ascendis Pharma A  3.14 $ 925.557  Millions$ 294.950  Millions
Dar Bioscience Inc   2.94 $ 32.714  Millions$ 11.112  Millions
Cymabay Therapeutics Inc   2.92 $ 105.698  Millions$ 36.154  Millions
Kineta Inc   2.85 $ 13.011  Millions$ 4.570  Millions
Spectrum Pharmaceuticals Inc   2.71 $ 75.450  Millions$ 27.888  Millions
Mersana Therapeutics Inc   2.63 $ 242.283  Millions$ 92.057  Millions
Ocular Therapeutix Inc   2.60 $ 91.845  Millions$ 35.379  Millions
First Wave Biopharma Inc   2.55 $ 2.698  Millions$ 1.058  Millions
Mirum Pharmaceuticals Inc   2.54 $ 210.869  Millions$ 83.083  Millions
Nrx Pharmaceuticals Inc   2.48 $ 18.407  Millions$ 7.409  Millions
Celyad Oncology Sa  2.47 $ 11.966  Millions$ 4.835  Millions
Rockwell Medical inc   2.47 $ 32.529  Millions$ 13.185  Millions
Eagle Pharmaceuticals inc   2.46 $ 172.600  Millions$ 70.200  Millions
Ibio inc   2.46 $ 32.977  Millions$ 13.425  Millions
Pieris Pharmaceuticals Inc   2.42 $ 67.561  Millions$ 27.929  Millions
Oncotelic Therapeutics Inc   2.35 $ 16.708  Millions$ 7.122  Millions

Date modified: 2023-05-17T06:15:39+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com